TG Therapeutics, Inc. (TGTX)
63.34
-1.54
(-2.37%)
USD |
NASDAQ |
Nov 20, 16:00
63.25
-0.09
(-0.14%)
After-Hours: 20:00
TG Therapeutics Research and Development Expense (TTM) : 236.22M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 236.22M |
| June 30, 2026 | 225.80M |
| March 31, 2026 | 162.25M |
| December 31, 2025 | 160.22M |
| September 30, 2025 | 142.90M |
| June 30, 2025 | 122.16M |
| March 31, 2025 | 107.93M |
| December 31, 2024 | 94.29M |
| September 30, 2024 | 87.86M |
| June 30, 2024 | 82.48M |
| March 31, 2024 | 93.05M |
| December 31, 2023 | 76.19M |
| September 30, 2023 | 88.38M |
| June 30, 2023 | 94.43M |
| March 31, 2023 | 93.18M |
| December 31, 2022 | 125.35M |
| September 30, 2022 | 158.36M |
| June 30, 2022 | 189.53M |
| March 31, 2022 | 207.53M |
| December 31, 2021 | 222.58M |
| September 30, 2021 | 202.89M |
| June 30, 2021 | 201.39M |
| March 31, 2021 | 192.97M |
| December 31, 2020 | 165.90M |
| September 30, 2020 | 153.88M |
| Date | Value |
|---|---|
| June 30, 2020 | 161.40M |
| March 31, 2020 | 157.82M |
| December 31, 2019 | 154.18M |
| September 30, 2019 | 175.51M |
| June 30, 2019 | 150.92M |
| March 31, 2019 | 156.76M |
| December 31, 2018 | 159.39M |
| September 30, 2018 | 133.11M |
| June 30, 2018 | 126.86M |
| March 31, 2018 | 114.87M |
| December 31, 2017 | 102.53M |
| September 30, 2017 | 98.82M |
| June 30, 2017 | 93.47M |
| March 31, 2017 | 80.30M |
| December 31, 2016 | 69.23M |
| September 30, 2016 | 62.20M |
| June 30, 2016 | 51.98M |
| March 31, 2016 | 49.71M |
| December 31, 2015 | 47.71M |
| September 30, 2015 | 47.59M |
| June 30, 2015 | 49.71M |
| March 31, 2015 | 45.29M |
| December 31, 2014 | 40.09M |
| September 30, 2014 | 28.71M |
| June 30, 2014 | 18.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Amneal Pharmaceuticals, Inc. | 182.00M |
| Vertex Pharmaceuticals, Inc. | 4.250B |
| Arrowhead Pharmaceuticals, Inc. | 929.60M |
| Insmed, Inc. | 944.39M |
| Ionis Pharmaceuticals, Inc. | 921.08M |